Epigenetic perspectives on systemic autoimmune disease.
Panagiota Karagianni, Athanasios G Tzioufas
https://pubmed.ncbi.nlm.nih.gov/31421964/Actively Recruiting
Led by CytoCares Inc · Updated on 2026-04-14
6
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety, tolerability, pharmacokinetics, and early effectiveness of CC312 in adults aged 18 to 65 with relapsed or refractory autoimmune diseases such as Systemic Lupus Erythematosus SLE, Idiopathic Inflammatory Myopathies IIM, and Systemic Sclerosis SSc. This early-phase, open-label study is investigator-initiated and sponsored by CytoCares Inc. The study involves administering CC312 intravenously in a series of doses starting with a priming dose on Day -3, followed by therapeutic doses on Days 1, 4, 8, and 11. After evaluating safety, B-cell depletion, and clinical response on Day 14, the dose may be maintained or increased, with additional doses given on Days 15, 18, 22, and 25. Safety and tolerability are assessed throughout the dosing schedule. Participants will undergo regular safety and tolerability assessments, alongside laboratory tests measuring drug levels, immune cells, antibodies, and disease activity scores such as the SLE Responder Index and modified Rodnan Skin Score. The study will monitor adverse events and dose-limiting toxicities over two years, tracking multiple disease activity markers and patient and physician global assessments. The total study duration allows for comprehensive monitoring of safety and preliminary efficacy.
CONDITIONS
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
C
CEO
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CytoCares Inc
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 4 weeks
Participants receive intravenous doses of CC312 starting with a priming dose three days before Day 1, followed by therapeutic doses on Days 1, 4, 8, 11, and then additional doses on Days 15, 18, 22, and 25 based on clinical evaluation. Safety and tolerability assessments are performed with each dose.
9 visits (in-person) for dosing and safety assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Panagiota Karagianni, Athanasios G Tzioufas
https://pubmed.ncbi.nlm.nih.gov/31421964/Andrea Doria, Zahir Amoura, Ricard Cervera...
https://pubmed.ncbi.nlm.nih.gov/23264339/Nathalie Conrad, Shivani Misra, Jan Y Verbakel...
https://pubmed.ncbi.nlm.nih.gov/37156255/CytoCares Inc
Lead Sponsor